미국 · 보도자료 · Ultragenyx Pharmaceutical Inc. · 2026-10-07 12:30
희귀 소아질환 우선심사바우처 2억 1000만 달러에 매각
NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the fi
Ultragenyx Pharmaceutical Inc. 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
